ARVN
Arvinas Inc
NASDAQ · Pharmaceuticals
$13.48
+0.52 (+4.01%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 235.28M | 132.17M | 248.87M | 233.97M | 279.36M |
| Net Income | -177,663,667 | -89,824,897 | 33.41M | 39.13M | 45.19M |
| EPS | — | — | — | — | — |
| Profit Margin | -75.5% | -71.7% | 13.4% | 16.7% | 16.2% |
| Rev Growth | +78.0% | +78.0% | +3.5% | +1.6% | -9.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 475.6K | 475.6K | 112.68M | 97.71M | 100.55M |
| Total Equity | 432.40M | 432.40M | 447.83M | 421.09M | 435.13M |
| D/E Ratio | 0.00 | 0.00 | 0.25 | 0.23 | 0.23 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -221,972,009 | -118,461,551 | 74.31M | 67.61M | 80.57M |
| Free Cash Flow | — | — | 30.36M | 28.90M | 31.70M |